Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

Documenti analoghi

• PLGA‐particle‐based vaccine induces SARS‐CoV‐2‐specific antibody and T‐cell responses
  di: Dennis Horvath, et al.
  Pubblicazione: (2026)
• The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19
  di: Henrietta Papp, et al.
  Pubblicazione: (2024)
• Effects of vaccines targeting interleukin‐1 receptor, type I on atrial and ventricular function after myocardial infarction
  di: Jianwu Huang, et al.
  Pubblicazione: (2026)
• Identification of risk factors for adverse drug reactions in a pharmacovigilance database
  di: S. Attelind, et al.
  Pubblicazione: (2024)
• Assessing the feasibility of infusing slow normal saline through a three‐metre‐longline to maintain patency of a peripheral venous cannula: A pilot study
  di: Anaelle Lubila, et al.
  Pubblicazione: (2025)